Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
Invasive aspergillosis (IA) is a leading cause of infection-related mortality in hematologic patients, with death rate ranging from 50 to 90%. 1 The reason for this extremely poor outcome is because of the difficulties in a timely and undoubted diagnosis, which still relies on a very high degree of suspicion. The current diagnostic tools are limited by invasiveness, slowness, relative insensitiveness, lack of standardization and unpredictable kinetics. 2 The most widely studied test, Galctomannan antigenemia (GM), has been demonstrated to be highly variable in performance, with sensitivity ranging between 29 and 100%, and is affected by several factors related either to the fungus or to the host. 2 Furthermore, the detection of Aspergillus DNA through polymerase chain reaction (PCR) is still hampered by the difficulties in understanding the fungal DNA release and kinetics other than by technical barriers. 2 For all these reasons, establishing an early diagnosis of IA remains a challenge. 1, 2 Recent studies have shown that adaptive immunity contributes to the host defense against Aspergillus species. 3 In the murine model of IA, mice resistant to the infection produce a high pulmonary level of T helper1 (T H 1) cytokines, whereas mice with a high level of T helper2 (T H 2) cytokines suffer from disease progression. 4 In a human clinical setting, a study has measured the production of either interferon-g (IFN-g) or interleukin-10 (IL-10) in culture supernatants of peripheral blood mononuclear cells (PBMCs) stimulated with Aspergillus antigens, showing that patients with high IFN-g/IL-10 ratio survive IA. 5 Moreover, the adoptive transfer of Aspergillusspecific IFN-g-producing T-cells (IFN-g-T H 1) has been reported to cure IA in allogeneic bone marrow transplant (alloBMT) patients. 6 To evaluate whether enumeration of Aspergillus-specific IFNg-T H 1 and Aspergillus-specific IL-10-producing T-cells (IL-10-T H 2) through an ex vivo enzyme-linked immunospot (ELISPOT) assay could improve the diagnosis and the clinical management of IA, we report the first clinical application of ELISPOT in a series of 10 hematologic patients with neutropenia and pulmonary infiltrates, including three of them with proven IA, as well as two healthy blood donors. ELISPOT has been performed on frozen peripheral blood samples, as described by Lalvani et al. 7 The study was approved by our institution review board. All patients gave their informed consent to the study. All patients were receiving antifungal prophylaxis with itraconazole 200 mg/b.i.d. when peripheral blood specimens were collected. PBMCs from either patients or healthy subjects were separated by using Ficoll-Hypaque gradient centrifugation (Linaris, Bettingen am Main, Germany) and then cultured in a 96-well polyvinylidene difluoride-bached plate coated with either anti-IFN-g or IL-10 monoclonal antibody (Mabtech, Nacka Strand, Sweden). Cells were stimulated with heatinactivated conidia, prepared from a patient's Aspergillus fumigatus isolate, or with a water-soluble cellular extract of Aspergillus fumigatus and with phytohemoagglutinin. A total of 1 Â 10 5 and 2.5 Â 10 4 cells/well were cultured in the IFN-g and IL-10 assay, respectively, for 16 h. All test conditions were carried out in triplicate and the results were considered positive if the number of spot-forming cells (SFC)/10 6 cells in Aspergillus antigen-stimulated wells was twofold higher than that in control wells (non-Aspergillus antigen-stimulated cells) and there were at least 20 spots. The assay was performed by one of the authors (PB), blinded to the patients' radiologic and clinical histories and personal identifiers, using an automated ELISPOT counter (AID-GmbH, Strassberg, Germany).
Patient 1 was a 59-year-old woman with acute myeloid leukemia (AML), presenting fever and an ovalar nodule surrounded by a halo of ground glass opacity (GG-O) in the left lung, detected at high-resolution computed tomography (HRCT) during neutropenia following induction chemotherapy (iCHT) (Figure 1b , 07/01/05). Cultural and molecular examination of blood, urine, feces and bronchoalveolar lavage fluid (BALf) were repeatedly negative for bacterial, fungal or viral pathogens. GM was negative either on serum or on BALf. Fever persisted despite vancomicine, meropenem and liposomal amphotericine B (L-amB) at 3 mg/kg/day. A second HRCT showed enlargement of the nodular opacity with unmodified GG-O. Serum GM was negative ( Figure 1b , 07/06/05). The L-amB dose was increased to 5 mg/kg/day. A few days later, the patient became afebrile, concomitantly with full hematologic recovery. After 1 week, HRCT showed a slight reduction of both the GG-O and the nodular lesion, with cavitation and air crescent formation (Figure 1b , 07/14/05). The patient underwent a video-assisted thoracoscopic (VATS) resection of the pulmonary consolidation. Histological and immunohistochemical examination disclosed IA.
Patient 2 was a 67-year-old woman, with neutropenia following iCHT for AML, developing fever and bilateral pulmonary infiltrates. Cultural and molecular examination of blood, urine, feces and BALf were negative for bacterial, fungal or viral pathogens. Second-line empirical antibiotic treatment led to the resolution of all but one pulmonary infiltrate, which enlarged in the right upper lobe, as detected by HRCT. A repeated complete cultural and molecular examination of blood, urine, feces and BALf remained negative for pathogens. GM antigenemia was negative on serum and positive on BALf. L-amB was started at 3 mg/kg/day. The patient's bone marrow function recovered and complete hematologic remission (CHR) was achieved. After one month of treatment, the pulmonary infiltrate reduced slightly, presenting a small air crescent sign. Before the start of consolidation chemotherapy (cCHT), the patient underwent surgical excision of the pulmonary lobe. Histologic and immunohistochemical examination revealed IA. During the early phase of surgical wound healing, AML relapsed and the patient died of progressive disease ten days later.
Patient 3 was a 24-year-old man with acute lymphoblastic leukemia (ALL), developing fever and a perihilar nodular lesion of the left lung during the neutropenic phase of iCHT. Cultural and molecular examination of blood, urine, feces and BALf were negative for bacterial, fungal or viral pathogens. GM was negative either on serum or on BALf. Cytological examination of the BALf disclosed fungal hyphae. Voriconazole was started at a dose of 200 mg i.v. b.i.d. After 2 weeks of treatment, the nodular lesion was not reduced and showed a small area of cavitation. As the patient presented an episode of hemophthisis, surgical resection of the upper segment of the left lower lobe was promptly performed. Histologic and immunohistochemical examination revealed IA. The patient achieved CHR, completed two courses of cCHT and is actually undergoing maintenance CHT treatment.
The clinical characteristics of seven more patients (pts 4-10), with diagnosis of the pulmonary disease as detected by HRCT, are reported in Table 1 . The etiology of the pneumonia has been documented by either cultures or histology in all seven patients.
In patient 1, the ELISPOT assay was performed on blood samples collected between the first and second HRCT, concomitantly with the third HRCT, 1 and 3 weeks after VATS, respectively. ELISPOT was positive for IL-10-T H 2 at each determination and showed increasing positivity for IFN-g-T H 1 (Figure 1a) . In patient 2, the ELISPOT assay was performed at the time of the HRCT, a few days before the surgical procedure and at the time of AML relapse. ELISPOT was positive for IL-10-T H 2 at the first and second determination, and showed positivity for IFN-g-T H 1 at the second determination. The third determination was negative for specific T-cell responses (Figure 1c) . In patient 3, the ELISPOT assay was performed at the time of the surgical procedure and after 15 days, before the first and second cCHT courses. ELISPOT was positive for IL-10-T H 2 at the first and second determination and showed positivity for IFN-g-T H 1 at each determination (Figure 1d ). The ELISPOT assay, which has been performed at the time of diagnosis of the pulmonary Letters to the Editor disease in patients 4-10, was negative for both IFN-g-T H 1 and IL-10-T H 2 responses (Figure 1e) .
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Moreover, the Aspergillus-specific T-cell response has been assessed in two healthy subjects. The ELISPOT assay almost reached the cut off value for IFN-g-T H 1 in both individuals, but not for IL-10-T H 2 (Figure 1e) .
The ELISPOT has provided the proof of IA in all three patients with the proven infection. In particular, the positive ELISPOT result represented the only proof in patient 1, in whom the diagnosis has been reached only after surgical procedure, all the other available tests, including GM, being repeatedly negative. The ELISPOT represented an improvement of the diagnostic yield of BALf GM and BALf cytology in patients 2 and 3, respectively. Thus, our positive findings demonstrate the potential of ELISPOT in the diagnosis of IA, and, combined with the negative results in control patients with pneumonia of non-fungal etiology, may spur further studies to validate its use as a new tool for the early diagnosis of IA in all high-risk patients, including those receiving either alloBMT or solid organ transplantation. The assay requires a short time interval to be performed and appears not to be influenced either by the patient's neutropenic state or by the assumption of antifungal prophylaxis. The ELISPOT assay applied to peripheral blood, in combination with other diagnostic modalities (GM or PCR), may strengthen a diagnosis of IA, possibly also reducing the use of invasive diagnostic techniques. The ELISPOT results in the healthy subjects were consistent with a previous study showing that the production of IFN-g, but not IL10, in culture supernatants of PBMCs stimulated with Aspergillus antigens in healthy individuals is indicative of a protective immunity against Aspergillus.
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The ELISPOT assay has also provided the first description of the kinetics of the human response to an IA during the course of the disease in vivo, showing (1) high levels of IL-10-T H 2 at the onset in all three patients, and during progression in patients 1 and 2; (2) growing levels of IFN-g-T H 1, required to achieve regression in all three patients; (3) sustained levels of IL-10-T H 2, which may exert a sort of a counterbalance effect to the growing levels of IFN-g-T H 1 to avoid an excessive inflammatory reaction in patient 1, patient 3 and partially in patient 2, similar to what has been observed in the mouse model; 3 and (4) persistence of an IFN-g-T H 1 response 2 months after the removal of the lesion in patient 3, indicative of the restoration of a protective immunity, similar to what has been observed in healthy subjects (Figure 1a, c and d) . In patient 2, the leukemia relapse probably hampered the long-lasting rise of IFN-g-T H 1 and the maintenance of a specific T-cell response (Figure 1c) . Furthermore, in patients 1 and 2, the kinetics of the ELISPOT appear to correlate well with the changes of the radiologic signs in IA: 8 an initial increase of the size of the pulmonary lesions associated with a high level of IL-10-T H 2 was followed by stability and gradual reduction of the size of the pulmonary lesion associated with an increasing IFN-g-T H 1 level (Figure 1a and b) . The delayed appearance of radiologic signs of reduction of the pulmonary lesion in patient 2 (not shown), compared with patient 1, is likely to be related to the delayed rise of IFN-g-T H 1 in the former (Figure 1a and c) .
By extending previous findings, 3, 5, 6 this assay may represent a step forward in understanding the paradigm of the IFN-g-T H 1/IL-10-T H 2 dynamic skewing at each time point of IA, with possible consequences in designing therapeutic strategies in high-risk patients.
